- Home
- BYSI vs MDXH Comparison
BYSI vs MDXH Comparison
Compare BYSI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- MDXH
- Stock Information
- Founded
- BYSI 2010
- MDXH 2003
- Country
- BYSI United States
- MDXH Belgium
- Employees
- BYSI N/A
- MDXH N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- BYSI Health Care
- MDXH
- Exchange
- BYSI Nasdaq
- MDXH Nasdaq
- Market Cap
- BYSI 72.1M
- MDXH 73.3M
- IPO Year
- BYSI 2017
- MDXH 2021
- Fundamental
- Price
- BYSI $1.46
- MDXH $1.45
- Analyst Decision
- BYSI
- MDXH Buy
- Analyst Count
- BYSI 0
- MDXH 1
- Target Price
- BYSI N/A
- MDXH $6.00
- AVG Volume (30 Days)
- BYSI 14.1K
- MDXH 99.9K
- Earning Date
- BYSI 01-01-0001
- MDXH 04-30-2025
- Dividend Yield
- BYSI N/A
- MDXH N/A
- EPS Growth
- BYSI N/A
- MDXH N/A
- EPS
- BYSI N/A
- MDXH N/A
- Revenue
- BYSI N/A
- MDXH $90,049,000.00
- Revenue This Year
- BYSI N/A
- MDXH $23.38
- Revenue Next Year
- BYSI N/A
- MDXH $16.84
- P/E Ratio
- BYSI N/A
- MDXH N/A
- Revenue Growth
- BYSI N/A
- MDXH 28.29
- 52 Week Low
- BYSI $1.37
- MDXH $1.35
- 52 Week High
- BYSI $3.63
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- BYSI 26.61
- MDXH 34.12
- Support Level
- BYSI $1.46
- MDXH $1.55
- Resistance Level
- BYSI $1.65
- MDXH $1.66
- Average True Range (ATR)
- BYSI 0.11
- MDXH 0.08
- MACD
- BYSI -0.03
- MDXH 0.00
- Stochastic Oscillator
- BYSI 2.13
- MDXH 11.90
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.